‘Disadvantaged’ Gilead flipped partner negotiations into M&A discussion ahead of $4.9B Forty Seven deal

How Forty Seven turned conversations with potential partners into a two-horse race for a buyout

As four companies negotiated for partnerships with Forty Seven around its lead asset, magrolimab, Gilead’s relative commercial weakness in cancer appeared to inspire the company to seek an M&A deal instead, leading to the eventual $4.9 billion offer that Forty Seven accepted early last week.

Forty Seven Inc. (NASDAQ:FTSV) CEO Mark McCamish told BioCentury on Wednesday that Gilead Sciences Inc. (NASDAQ:GILD) may have been “disadvantaged” compared with other parties working to complete a deal. Instead, Gilead

Read the full 751 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers